Vaccine The vaccine vector virus, designated as Ad4-H5-Vtn, is a recombinant, replication-competent Ad4, encoding full-length hemagglutinin (HA) from H5N1 influenza virus (A/Vietnam/1194(A/Vietnam/ /2004 1 . The recombinant virus was derived from the US Military Ad4 vaccine virus which had been originally isolated from a military recruit with acute respiratory disease before being passaged in WI-38 cells 2 . The H5 HA transgene was modified to include a specific deletion/mutation of the polybasic protein cleavage domain (ΔPCS) that blocks cleavage of full-length HA into the active subunits 3 . This mutation is required in the generation of traditional, inactivated H5N1 virus vaccines. The H5 gene was cloned into a minor deletion in the E3 region of Ad4 which increased the cloning capacity while preserving the known functions of E3.The expression cassette was modified to include sequences that would link the expression of H5-HA with the adenovirus major late promoter, which exerts its activity over a long range by carefully controlled RNA splicing.
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11 vp/dose) or placebo, each dose given approximately 56 days apart. Enrollment was restricted to healthy men and non-pregnant women, ages 18 to 40. Based on experience with the military Ad4 vaccine, intestinal replication and shedding of the Ad4-H5-Vtn virus and possible transmission of the vaccine virus was anticipated and therefore enrollment was restricted to subjects who either lived alone or had no more than two healthy, adult (ages 18-65) household contacts (HHCs) who were also willing to be enrolled in the study in order to evaluate potential transmission of Ad4-H5-Vtn virus.
Escalation of dosage and administration of a second or third dose within a cohort was determined by a systematic and independent safety review. When clinical and virological data through 14 days post-vaccination was available from at least 90% of the Ad4-H5-Vtn recipients and associated HHCs, the data was reviewed by PaxVax and an independent safety, data monitoring committee (DMC) with a focus on the occurrence of any severe adverse events, evidence of systemic spread of the Ad4-H5-Vtn vaccine virus, or evidence of potential Ad4-related disease in the HHCs. If there were no significant safety issues identified, the subjects received their second or third dose administration, and the next, higher dosage cohort was enrolled.
Safety in vaccinated subjects was monitored by documenting solicited reactogenicity using a 7-day subject diary after each vaccination and unsolicited adverse events throughout the study. In addition, clinical laboratory tests (hematology, chemistry, and urinalysis) were conducted at baseline and 7-days after each vaccination. Rectal swabs, throat swabs, and blood were collected for evaluation of Ad4-H5-Vtn virus shedding by Ad4-H5-Vtn-specific PCR; any samples that were positive for Ad4-H5-Vtn by PCR were further evaluated in an Ad4-H5-Vtn-specific culture assay. Safety in HHCs was monitored by documentation of adverse events and by evaluating potential transmission of Ad4-H5-Vtn virus by PCR (rectal and throat swabs) 14 days after each immunization in the vaccinee, and by Ad4 and H5 HA seroconversion with blood specimens at 56 days after each immunization in the vaccinee.
Additional physical examinations, safety laboratory tests, and pregnancy tests were performed on any Vaccinee or HHC, if indicated by the results of scheduled safety assessments or if they presented with signs or symptoms of potential adenovirus syndromes, such as fever, upper respiratory illness, nephritis/cystitis, conjunctivitis, or diarrhea. These tests included surveillance for Ad4-H5-Vtn infection by PCR, and then culture, if the PCR were positive of blood, rectal and throat swabs, and of other appropriate clinical specimens such as urine or conjunctival swabs.
Immunological and virological assays
Hemagglutination-inhibition (HAI): The H5N1 HAI assay was performed by Focus Diagnostics, Irvine, CA using a modification of the WHO method 5 . Prior to the HAI assay, all serum samples from human subjects were treated with receptor destroying enzyme (RDE) overnight at 37°C and determined to be free of non-specific inhibitors. Serial 2-fold dilutions of sera were incubated for 20 minutes at 37°C with the fixed concentration of 4 hemagglutination units (4 HAU) of standard H5N1 antigen (inactivated recombinant H5N1 influenza A virus, source: NIBSC). A 0·75% suspension of horse red blood cells (hRBC, Lampire, Pipersville, PA) was then added to each well and incubated at room temperature for 2 hours. The HAI titer was determined as the reciprocal of the last dilution of sera that completely inhibited hemagglutination. Wells containing hRBC only (no virus or serum), hRBC + 4 HAU virus (no serum), virus backtitration, and testing of positive and negative control sera were used in each assay as quality controls.
Ad4 neutralization:
The Ad4 microneutralization assay was performed by Focus Diagnostics. Serial dilutions (1:4 to 1:8192) of the test sera were incubated for approximately one hour with a known concentration of reference virus. A549 cells were then added to the virus serum neutralization mix and incubated for 7 days. The adenovirus neutralizing antibody was then detected and quantitated by the use of a colorimetric assay 6 . The neutralizing titer 50 (NT50) of the test sera is measured by determining the serum dilution that gives a 50% protection in CPE when compared to the cell-only control. Samples were tested in 6 repeats and NT50 was determined by use of the Karber formula.
H5N1 microneutralization (MN)
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: The MN assay was performed in the laboratory of Richard Webby, St. Jude's, Memphis, TN. Serum levels of H5-specific neutralizing antibody were detected by microneutralization assay on MDCK cells grown to near confluency in 96-well plates. One hundred 50% tissue culture infectious doses of the attenuated A/Vietnam/1203/2004 (H5N1) vaccine virus was incubated with serial two-fold dilutions of each serum sample. Serum and virus mixtures were done in triplicate and incubated at 37°C for 1 hr. After incubation, the growth media was removed from the MDCK cells and the serum-virus mixes added. After a further 1hr incubation at 37°C, the mixes were aspirated from each well of the 96-well plate, the cells washed twice in PBS, then fresh media containing 1mg/ml TPCK-treated trypsin was added to each well. Plates were incubated for 72 hours at 37°C and the presence of virus determined by hemagglutination assay with chicken red blood cells. Neutralizing titers were expressed as the reciprocal of the serum dilution that inhibited 50% of the growth.
. The capture and detection anti-IFN- monoclonal antibodies used were clone 1D1K and the clone 7-B6-1 (Mabtech, Mariemont, OH), respectively. For IL-2 responses, antibody from clone 5334 (R&D Systems, Minneapolis, MN) and BG5 (biotinylated, ThermoFisher Pierce Protein; Rockville, IL) were used. PBMC samples from each subject were typically batch tested in the same experiment, always with a pre-vaccination sample to accurately assess differences in pre-and post-vaccine responses. After thawing and resting overnight in culture, PBMC (2x10 5 cells/well) were stimulated in triplicate wells with 4 µg/ml of recombinant H5N1 HA protein (Protein Sciences, Meridien, CT) or with 4 pools of overlapping peptides of the HA transgene sequence. Peptides (133 total), 15 residues in length and overlapping by 11 residues, were synthesized and purified by HPLC (>95% purity) by A & A Laboratory (San Diego, CA). Each pool consisted of 33 or 34 peptides total and was tested at a final concentration of 2·5 µg/ml per peptide. As a positive control, each PBMC sample was also tested against the CEF peptide pool (AnaSpec, Fremont, CA) 10 and PHA-P mitogen (Sigma-Aldrich, St. Louis, MO). After incubation for 16-22 hr at 37 C, wells were washed with PBS-0·05% Tween-20 (Sigma-Aldrich) to remove cells then incubated with biotinconjugated capture antibody. Spots were subsequently developed by incubation with avidin-peroxidase complex (Vectastain ABC, Vector Laboratories; Burlingame, CA) followed by tetramethylbenzidine (TruBlue peroxidase substrate, KPL; Gaithersburg, MD). Spots were enumerated with a computer-assisted ELISPOT reader formatted with image capture and counting software (C.T.L.; Shaker Heights, OH). Vaccine induced responses were scored positive if they exceeded 80 net spots/10 6 cells, after subtracting the no-antigen background, and were >4-fold above the pre-vaccine response. Statistical methods Safety and immunogenicity were prospectively specified as co-primary objectives. Safety endpoints included solicited signs and symptoms of reactogenicity reported for 7 days post vaccination on a diary card; unsolicited adverse events; and PCR analyses of rectal, throat and blood samples for evidence of excreted or systemic vaccine virus. Household contacts (HHCs) were monitored at regular intervals for evidence of Ad4-H5-Vtn transmission through PCR analyses of rectal and throat samples, and by serum Ad4 microneutralization assay. Adverse events were also collected for HHCs. Two primary immunogenicity endpoints were pre-specified: seroconversion by H5N1 HAI, defined by a 4-fold rise over the pre-vaccination titer, and HAI geometric mean titer (GMT). Additional endpoints included serum H5N1 microneutralization and H5N1 HA-specific ELISA; cellular immune response measured by ELISPOT; serum Ad4 antibody microneutralization; and vaccine "take" defined as either detection of Ad4-H5-Vtn in a rectal sample or Ad4 seroconversion.
Ad4-H5-Vtn
The sample size of 24 vaccine recipients per treatment group was determined by the HAI seroconversion endpoint. Specifically, power to detect a two-fold difference in the seroconversion rate between any two treatment groups was estimated at 76% assuming use of a two-sided Fisher's exact test with p=0·05, and assuming the rate in the better performing group was 80%.
Subjects were enrolled in ascending dose cohorts and randomized in 3:1 ratio to either Ad4-H5-Vtn vaccine or placebo. At each site an independent, unblinded pharmacist dispensed either vaccine or placebo according to a computer-generated randomization list with a block size of 8. Subjects, HHCs, investigators, study site personnel, and medical monitors were blinded to subjects' treatment assignment throughout treatment and follow-up. Unblinded administration of the boost vaccination was offered to both vaccine and placebo recipients. Postrandomization stratification was used for analyses of the impact of baseline Ad4 seropositivity.
Pre-boost reactogenicity rates were calculated from the percentage of subjects who reported a specific sign or symptom at least once following any of the three vaccinations with Ad4-H5-Vtn or placebo. The denominator following the first, second, and third vaccinations was the number of subjects who received the first, second, or third vaccination, respectively. Severity rates were determined by the highest severity reported by a subject for a particular sign or symptom. Confidence intervals for percentages were calculated by the Clopper-Pearson method, and pairwise comparisons between percentages were made using Fisher's exact test. Post-boost reactogenicity rates were calculated from the subset of individuals who received the boost vaccination.
Pre-boost rates for vaccine take, seroconversion by either H5N1 or Ad4 antibodies, and cellular immune response were calculated on cumulative basis where the denominator was the number of subjects with a valid baseline measurement for a particular assay and at least one valid post-vaccination result. The denominator for post-boost rates was the number of subjects who had at least one pre-boost measurement and a valid post-boost result.
Confidence intervals for the geometric mean were estimated by log-transforming the data, constructing intervals based on the t distribution in the log domain, and back-transforming the resulting interval to the original scale. Pairwise comparisons of continuous endpoints were made using either t-tests performed on log-transformed data or Wilcoxon tests.
Analyses were specified in a statistical analysis plan. Analyses and sample size estimation were performed using SAS 9·2, S-Plus 7·0, StatXact 8, and nQuery Advisor 5·0. For each category of reactogenicity, "Any" refers to the percent (95% CI) of subjects who reported that symptom at least once following any of the three vaccinations with Ad4-H5-Vtn or placebo. For "Mild," "Moderate," and "Severe", a subject is counted once at the highest severity level he or she reports.
Safety
The group comprised of all Ad4-H5-Vtn recipients reported significantly more abdominal pain (p=0·017)*, diarrhea (p=0·027) †, and incidences of nasal congestion/runny nose (p=0·028) ‡ than placebo recipients. Table S A vaccinee is counted once within each category if he/she reports reactogenicity at least once in that category. All subjects who received the boost vaccination completed diary cards; percentages are calculated from the number of subjects in each treatment group. *p=0.042. Both placebo recipients who reported chills graded the symptoms as mild. †p=0.020. All 17 Ad4-H5-Vtn recipients who reported injection site pain graded it as mild. Seroconversion requires a 4-fold rise over baseline value. Percentages and GMTs are calculated from subjects (N) who had a baseline result and at least one post-vaccination result. 
Replication of Ad4-H5-vtn vaccine virus
